$25 Million

Alimera Sciences, Inc.

Follow-on Offering

Sole Bookrunner, August 2016

Confidentially Marketed Public Offering

Alimera Sciences is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. It is presently focused on diseases affecting the back of the eye, or retina, due to a poor standard-of-care and a sizeable market opportunity. Alimera’s only commercial product is ILUVIEN®, which has been developed to treat diabetic macular edema, or DME. DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. ILUVIEN has received marketing authorization in the U.S., Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, Sweden and the United Kingdom. In the U.S., ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure, or IOP. In the European Economic Area (EEA) countries in which ILUVIEN has received marketing authorization, it is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.